Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COPS5 | Q92905 | 5/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20551752 | 0.81 | ALDH1A1 (0.36) | COPS5TDP1ALDH1A1HPGD | |
| SCHEMBL5521979 | 0.78 | ALDH1A1 (0.37) | COPS5RAF1ALDH1A1HPGDMEN1 | |
| SCHEMBL3207166 | 0.76 | ALDH1A1 (0.53) | ALDH1A1HPGDMEN1CYP1A2KMT2A | |
| SCHEMBL2829075 | 0.74 | SMN1; SMN2 (0.38) | COPS5TDP1ALDH1A1HPGDCYP1A2 | |
| SCHEMBL15534756 | 0.71 | COPS5 (0.39) | COPS5TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4686476 | 0.70 | GRM6 (0.40) | COPS5ALDH1A1HPGDMEN1CYP1A2 | |
| SCHEMBL1489356 | 0.69 | LMNA (0.41) | COPS5TDP1ALDH1A1HPGDMEN1 | |
| SCHEMBL15472483 | 0.69 | RAF1 (0.34) | COPS5RAF1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL2474416 | 0.69 | GABRP (0.36) | COPS5TDP1ALDH1A1HPGDCYP1A2 | |
| SCHEMBL17045320 | 0.69 | NOS1 (0.36) | KMT2ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010019930-A1 | UREA DERIVATIVES AS INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | COPS5 2608/4885RAF1 74/4885TDP1 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.